Gilead-Tango expand strategic partnership for immune evasion therapies
Category: #health  By Saipriya Iyer  Date: 2020-08-19
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Gilead-Tango expand strategic partnership for immune evasion therapies

Gilead Sciences and Tango Therapeutics have recently announced the expansion of their strategic partnership. The partnership is associated with the development, discovery, and commercialization of innovative & targeted immune evasion therapies for cancer patients.

Under the recently expanded multi-year collaboration of the deal inked in 2018, Tango Therapeutics will continuously leverage its CRISPR-enabled, proprietary functional genomics target discovery platform, which will help identify the novel immune evasion targets. The company will also expand the number of targets covered from 5 to 15.

Additionally, Gilead will gain options to the global rights for programs that are directed to these targets for the next 7 years. The company will be able to pay the option extension fees to lead the activities via early clinical development for Tango, to which it will retain the option rights. Moreover, Tango will be provided with an option to co-develop & co-promote the lead products for over 5 programs in the U.S.

William A. Lee, Ph.D., EVP of Research at Gilead Sciences, has reportedly stated that the company has been driving its productivity and enhancing the quality of its scientific discovery through the partnership that was signed 2 years ago. It is also looking forward to continuing its partnership with Tango to further identify more sets of targets based on its immune-oncology strategy.

The deal excludes leading programs of Tango, including the one that is anticipated to be in IND (investigational new drug) application-enabling studies in 2021. Furthermore, Tango will retain the right to identify various targets outside the immune evasion category.

As per the terms of the agreement, Gilead will pay an upfront payment of $125 million to Tango, as well as an equity investment of $20 million in the company. Gilead will also gain the right to option over 15 programs across a 7-year span, for nearly $410 million per program in the extension, opt-in, and milestone payments. Moreover, Tango will be eligible to obtain low double-digit tiered royalties on the net sales.

Source credit:

https://www.businesswire.com/news/home/20200817005606/en/Gilead-Sciences-Tango-Therapeutics-Expand-Strategic-Oncology



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

Europe’s telecom bosses urge IT firms to split internet network costs

Europe’s telecom bosses urge IT firms to split internet network costs

By Saipriya Iyer

The heads of the largest telecom companies in Europe, including Vodafone, BT, and Deutsche Telekom, have called on Internet giants, such as Amazon and Netflix to share some of the escalating costs of dat...

Fidelity plans to offer Bitcoins to individual investors

Fidelity plans to offer Bitcoins to individual investors

By Saipriya Iyer

Fidelity clients will soon have access to the company's brokerage platform where they may purchase Bitcoin, as per credible reports.

One of the largest fund managers in the wo...

WholeHealth Living, Vori Health partner for musculoskeletal solutions

WholeHealth Living, Vori Health partner for musculoskeletal solutions

By Saipriya Iyer

WholeHealth Living, Inc., a Tivity Health® company delivering cost-effective integrated solutions, has reportedly entered a partnership agreement with Vori Health®, an all-inclusive health care provider practic...